November 21, 2023

PET scans of heart may aid early detection of Lewy body diseases

At a Glance

  • NIH scientists found that PET scans of the heart may help to identify which at-risk people will later develop Parkinsonā€™s disease or dementia with Lewy bodies.
  • The findings may lead to improved approaches for early detection of these Lewy body diseases.
Heart PET scans from a study participant. Heart PET scans from a study participant who developed Parkinsonā€™s disease. The top image is a 13N-ammonia PET scan, used to show where the blood flow is in the heart. The lower image, of the same heart, shows low 18F-dopamine-derived radioactivity, which appeared before symptom onset.Goldstein lab, NINDS

As the U.S. population grows older, thereā€™s been a rise in age-related neurodegenerative diseases. Two such diseases are Parkinsonā€™s disease and dementiaĀ with Lewy bodies. Because both involve abnormal structures, called Lewy bodies, inside nerve cells, they are referred to as Lewy body diseases. Lewy bodies contain a harmful form of a protein called alpha-synuclein. Symptoms of both diseases can include slow movement and cognitive impairment. Once symptoms arise, serious neurodegeneration has already occurred.

Researchers have been searching for ways to detect these Lewy body diseases earlier. Early diagnosis could help scientists study preventive approachesĀ like lifestyle changes, dietary supplements, or medications.

Five years ago, an NIH research team led by Dr. David S. Goldstein reported results from a study that followed 27 people for at least three years. All participants had three or more risk factors for Parkinsonā€™s disease. Risk factors included a family history of the disease,Ā a reduced sense of smell,Ā dream enactment behavior (a sleep disorder in which people act out their dreams),Ā and orthostatic intolerance (problems upon standing, such as fainting or lightheadedness).

The researchers found evidence, using an imaging technique calledĀ 18F-dopamine PET scanning,Ā that people who later were diagnosed with Parkinsonā€™s disease already had severe depletion of the chemical messenger norepinephrine in their hearts. Norepinephrine is derived from dopamine, which is lacking in particular brain centers in people with Parkinsonā€™s disease.

In a continuation of that study, the team has now assessed 34 at-risk people over a longer time period.Ā Participants underwent 18F-dopamine PET scanning every 18 months for up to 7.5 years or until they were diagnosed with Parkinsonā€™s disease. Results appeared in the Journal of Clinical Investigation on October 26, 2023.

The researchers confirmed that 18F-dopamine PET scans could distinguish the participants who would later be diagnosed with Parkinsonā€™s or dementiaĀ with Lewy bodies. Those who had low levels of 18F-dopamine-derived radioactivity in the heart were highly likely to develop Parkinsonā€™s or dementiaĀ with Lewy bodies. Of the nine people who had low radioactivity levels at their first scan, eight were later diagnosed with one of these Lewy body diseases. Of the 25 participants who initially had normal radioactivity levels, only one of the 11 who completed the sevenĀ years of follow-upĀ developed one of the diseases.

These findings support the view that disorders like Parkinsonā€™s and dementiaĀ with Lewy bodies feature early involvement of the autonomic nervous system, the system that regulates automatic body processes like heart rate and blood pressure.

ā€œWe think that in many cases of Parkinsonā€™s and dementia with Lewy bodies, the disease processes donā€™t actually begin in the brain,ā€ Goldstein explains. Rather, autonomic processes may malfunction in other body organs first, before the disease process reachesĀ the brain. ā€œThe loss of norepinephrine in the heart predicts and precedes the loss of dopamine in the brain in Lewy body diseases,ā€ he concludes.Ā 

Such indicators outside the brain may help researchers detect the earliest signs of Lewy body diseasesĀ before symptoms appear.

Related Links

References:  Goldstein DS, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S, Isonaka R, Wu T, Sharabi Y. J Clin Invest. 2023 Oct 26:e172460. doi: 10.1172/JCI172460. Online ahead of print. PMID:Ā 37883190.

Funding: NIHā€™s National Institute of Neurological Disorders and Stroke (NINDS) and National Human Genome Research Institute (NHGRI).